1. Home
  2. CRSP vs IBP Comparison

CRSP vs IBP Comparison

Compare CRSP & IBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRSP
  • IBP
  • Stock Information
  • Founded
  • CRSP 2013
  • IBP 1977
  • Country
  • CRSP Switzerland
  • IBP United States
  • Employees
  • CRSP N/A
  • IBP N/A
  • Industry
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • IBP Homebuilding
  • Sector
  • CRSP Health Care
  • IBP Consumer Discretionary
  • Exchange
  • CRSP Nasdaq
  • IBP Nasdaq
  • Market Cap
  • CRSP 4.1B
  • IBP 6.7B
  • IPO Year
  • CRSP 2016
  • IBP 2014
  • Fundamental
  • Price
  • CRSP $48.29
  • IBP $253.95
  • Analyst Decision
  • CRSP Buy
  • IBP Buy
  • Analyst Count
  • CRSP 19
  • IBP 10
  • Target Price
  • CRSP $73.94
  • IBP $254.40
  • AVG Volume (30 Days)
  • CRSP 974.9K
  • IBP 240.9K
  • Earning Date
  • CRSP 11-04-2024
  • IBP 11-06-2024
  • Dividend Yield
  • CRSP N/A
  • IBP 0.56%
  • EPS Growth
  • CRSP N/A
  • IBP 5.78
  • EPS
  • CRSP N/A
  • IBP 8.96
  • Revenue
  • CRSP $202,227,000.00
  • IBP $2,857,700,000.00
  • Revenue This Year
  • CRSP N/A
  • IBP $7.82
  • Revenue Next Year
  • CRSP $479.21
  • IBP $6.01
  • P/E Ratio
  • CRSP N/A
  • IBP $28.38
  • Revenue Growth
  • CRSP 18.89
  • IBP 3.65
  • 52 Week Low
  • CRSP $37.55
  • IBP $106.02
  • 52 Week High
  • CRSP $91.10
  • IBP $281.04
  • Technical
  • Relative Strength Index (RSI)
  • CRSP 56.29
  • IBP 63.78
  • Support Level
  • CRSP $44.44
  • IBP $231.77
  • Resistance Level
  • CRSP $45.76
  • IBP $259.59
  • Average True Range (ATR)
  • CRSP 1.33
  • IBP 8.06
  • MACD
  • CRSP 0.43
  • IBP 0.65
  • Stochastic Oscillator
  • CRSP 79.71
  • IBP 81.22

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for to treat Type 1 diabetes.

About IBP Installed Building Products Inc.

Installed Building Products Inc is an insulation installer serving the residential new construction market and are also a diversified installer of complementary building products, including waterproofing, fire-stopping and fireproofing, garage doors, rain gutters, window blinds, shower doors, closet shelving, mirrors and other products throughout the United States. The company installs fiberglass insulation, spray foam insulation, and cellulose insulation. The company has three operating segments consisting of Installation, Manufacturing and Distribution operations. Majority of revenue is generated from Installation segment.

Share on Social Networks: